<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04850560</url>
  </required_header>
  <id_info>
    <org_study_id>IR2021001123</org_study_id>
    <nct_id>NCT04850560</nct_id>
  </id_info>
  <brief_title>Sequential Low-dose Decitabine With PD-1/CD28 CD19 CAR-T in Relapsed or Refractory B-cell Lymphoma</brief_title>
  <official_title>Sequential Low-dose Decitabine Therapy With Novel CAR-T Carrying PD-1/CD28 Chimeric Switch Receptor in Relapsed or Refractory B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of CD19 PD-1/CD28-CAR-T sequential low-dose decitabine in&#xD;
      the treatment of relapse or refractory B cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>3 months</time_frame>
    <description>Objective response rate of the combination</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Objective Response Rate</condition>
  <arm_group>
    <arm_group_label>CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine</intervention_name>
    <description>CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine</description>
    <arm_group_label>CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  (1) Age ≥ 18, upper limit 75, unlimited for men and women;&#xD;
&#xD;
             (2) ECOG score 0-3;&#xD;
&#xD;
             (3) Histologically confirmed diffuse large B-cell lymphoma (DLBCL) [according to who&#xD;
             2008];&#xD;
&#xD;
             (4) CD19 was positive (immunohistochemistry or flow cytometry).&#xD;
&#xD;
             (5) The definition of refractory or relapse of DLBCL is: no complete remission after&#xD;
             2-line treatment; disease progression in any treatment process, or disease&#xD;
             stabilization time equal to or less than 6 months; or disease progression or relapse&#xD;
             within 12 months after hematopoietic stem cell transplantation;&#xD;
&#xD;
             (6) The previous treatment of diffuse large B cell lymphoma must include rituximab&#xD;
             (CD20 mAb) and anthracycline;&#xD;
&#xD;
             (7) There should be at least one measurable focus. It is required that any length of&#xD;
             lymph node focus should be greater than 1.5cm or any length of extranodal focus should&#xD;
             be greater than 1.0cm. PET-CT scan focuses should have uptake (SUV is greater than&#xD;
             liver blood pool);&#xD;
&#xD;
             (8) The absolute value of neutrophils in peripheral blood ≥ 1000 / μ L, platelet ≥&#xD;
             45000 / μ L;&#xD;
&#xD;
             (9) Heart, liver and kidney function: creatinine &lt; 1.5mg/dl; ALT (alanine&#xD;
             aminotransferase) / AST (aspartate aminotransferase) 2.5 times lower than the normal&#xD;
             upper limit; total bilirubin &lt; 1.5mg/dl; heart ejection fraction (EF) ≥ 50%;&#xD;
&#xD;
             (10) Sufficient understanding ability and voluntary signing of informed consent;&#xD;
&#xD;
             (11) Those with fertility must be willing to use contraceptive methods;&#xD;
&#xD;
             (12) According to the judgment of the researchers, the expected survival time is more&#xD;
             than 4 months;&#xD;
&#xD;
             (13) Willing to follow visit schedule, administration plan, laboratory inspection and&#xD;
             other test steps.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (1) History of other tumors;&#xD;
&#xD;
             (2) Hematopoietic stem cell transplantation was performed within 6 weeks;&#xD;
&#xD;
             (3) Any target car-t treatment was performed within 3 months before the car-t&#xD;
             treatment;&#xD;
&#xD;
             (4) Previous use of any commercially available PD-1 mAb;&#xD;
&#xD;
             (5) Cytotoxic drugs, glucocorticoids and other targeted drugs were received within 2&#xD;
             weeks before cell collection;&#xD;
&#xD;
             (6) Active autoimmune diseases;&#xD;
&#xD;
             (7) Uncontrollable infection of active bacteria and fungi;&#xD;
&#xD;
             (8) HIV infection, syphilis infection; active hepatitis B or C: hepatitis B: HBV-DNA ≥&#xD;
             1000IU / ml; hepatitis C: HCV RNA positive and liver function abnormal.&#xD;
&#xD;
             (9) Known central nervous system lymphoma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hui Liu, MD, PhD</last_name>
    <phone>13819198629</phone>
    <email>sylenliu@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wenbin Qian, MD, PhD</last_name>
    <phone>13605801032</phone>
    <email>qianwb@zju.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>2nd Affiliated Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>3100019</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Liu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 18, 2021</study_first_submitted>
  <study_first_submitted_qc>April 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2021</study_first_posted>
  <last_update_submitted>June 5, 2021</last_update_submitted>
  <last_update_submitted_qc>June 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

